title: Performance of the Framingham and SCORE cardiovascular risk prediction functions in a non-diabetic population of a Spanish health care centre: a validation study.
abstract: OBJECTIVE
  To analyse the 10-year performance of the original Framingham coronary risk function and of the SCORE cardiovascular death risk function in a non-diabetic population of 40-65 years of age served by a Spanish healthcare centre. Also, to estimate the percentage of patients who are candidates for antihypertensive and lipid-lowering therapy.
  
  
  METHODS
  Longitudinal, observational study of a retrospective cohort followed up for 10 years.
  
  
  METHODS
  Primary care health centre.
  
  
  METHODS
  A total of 608 non-diabetic patients of 40-65 years of age (mean 52.8 years, 56.7% women), without evidence of cardiovascular disease were studied.
  
  
  METHODS
  Coronary risk at 10 years from the time of their recruitment, using the tables based on the original Framingham function, and of their 10-year risk of fatal cardiovascular disease using the SCORE tables.
  
  
  RESULTS
  The actual incidence rates of coronary and fatal cardiovascular events were 7.9% and 1.5%, respectively. The original Framingham equation over-predicted risk by 64%, while SCORE function over-predicted risk by 40%, but the SCORE model performed better than the Framingham one for discrimination and calibration statistics. The original Framingham function classified 18.3% of the population as high risk and SCORE 9.2%. The proportions of patients who would be candidates for lipid-lowering therapy were 31.0% and 23.8% according to the original Framingham and SCORE functions, respectively, and 36.8% and 31.2% for antihypertensive therapy.
  
  
  CONCLUSIONS
  The SCORE function showed better values than the original Framingham function for each of the discrimination and calibration statistics. The original Framingham function selected a greater percentage of candidates for antihypertensive and lipid-lowering therapy.
authors.affiliation: Centro de Salud Universitario "La Paz", Badajoz, Spain.
authors.forename: Lourdes Cañón
authors.initials: LC
authors.lastname: Barroso
authors.forename: Eloísa Cruces
authors.initials: EC
authors.lastname: Muro
authors.forename: Natalio Díaz
authors.initials: ND
authors.lastname: Herrera
authors.forename: Gerardo Fernández
authors.initials: GF
authors.lastname: Ochoa
authors.forename: Juan Ignacio Calvo
authors.initials: JI
authors.lastname: Hueros
authors.forename: Francisco
authors.initials: F
authors.lastname: Buitrago
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000175:diagnosis* / Q000453:epidemiology / Q000517:prevention & control; D003151:Community Health Centers; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology
chemical_list: D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents